a study on Breast Cancer
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
Neoplasms, Breast VEGF Tyrosine kinase ErbB2 Her2-neu metastatic breast cancer EGFR ErbB1 bevacizumab lapatinib
Open to females ages 18 years and up
© The Regents of the University of California